Scottsdale – On February 2, the U.S. Food and Drug Administration approved Xiaflex (collagenase clostridium histolyticum) as the first drug to treat a progressive hand disease known as Dupuytren’s contracture.

Dupuytren’s contracture can affect a person’s ability to straighten and properly use their fingers. The disease process affects the connective tissue beneath the skin of the palm of the hand. When too much collagen builds up, it forms thick cords of tissue that prevent the fingers relaxing and straightening normally.

Xiaflex is a biologic drug made from the protein product of a living organism, a bacteria. The enzyme collagenase is derived from this organism. The medication works by breaking down the excessive buildup of collagen in the hand. Xiaflex is injected directly into the collagen cords and should be administered only by a health care professional experienced with injections of the hand.

Common adverse reactions included swelling, bleeding, and pain in the injected area. No serious allergic reactions have been observed, such a response would not be unexpected because this foreign protein could prompt an immune system reaction. (Source: FDA)